TargetBeta
DRD2
dopamine receptor D2 · also D2R · Dopamine receptors
15 programs in company-led studies act on DRD2, from 11 companies: 3 in phase 3, 10 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 153 running | HTR2A | ChEMBL |
| Aripiprazolerule | Otsuka | phase 4 | 1312 running | HTR1A, HTR2A | ChEMBL |
| lurasidonerule | Sumitomo Pharma | phase 4 | 522 running | HTR2A | ChEMBL |
| Cabergolinerule | Changchun GeneScience Pharmaceutical | phase 4 | 82 running | – | ChEMBL |
| Risperidonerule | Johnson & Johnson | phase 4 | 1111 running | HTR2A, HTR2C | ChEMBL |
| paliperidonerule | Johnson & Johnson | phase 4 | 1061 running | HTR2A | ChEMBL |
| Olanzapinerule | Eli Lilly | phase 4 | 761 running | DRD3, DRD4, HTR2A, HTR2C | ChEMBL |
| rotigotinerule | UCB | phase 4 | 641 running | DRD3, DRD4 | ChEMBL |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 441 running | DRD3, DRD4 | ChEMBL |
| brexpiprazolerule | Otsuka | phase 4 | 700 running | HTR1A, HTR2A | ChEMBL |
| lumateperonerule | Johnson & Johnson | phase 3 | 256 running | HTR2A, SLC6A4 | ChEMBL |
| cariprazinerule | AbbVie | phase 3 | 414 running | DRD3 | ChEMBL |
| pridopidinerule | Prilenia | phase 3 | 102 running | – | ChEMBL |
| ABBV-932 | AbbVie | phase 2 | 103 running | DRD3, HTR1A | the company's pipeline |
| zeltipronerule | Jazz Pharmaceuticals | phase 2 | 33 running | – | NCIt |
Conditions their studies are in
- Schizophrenia, 9 programs
- Bipolar Disorder, 8 programs
- Depressive Disorder, Major, 6 programs
- Parkinson Disease, 4 programs
- Restless Legs Syndrome, 3 programs
- Alzheimer Disease, 2 programs
- Autistic Disorder, 2 programs
- Depression, 2 programs
- Fasting, 2 programs
- Mania, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026ABBV-932 · AbbVie · phase 2 · NCT06846320
- Nov 21, 2026Cabergoline · Changchun GeneScience Pharmaceutical · phase 4 · NCT07124221
- Dec 15, 2026cariprazine · AbbVie · phase 3 · NCT03817502
- Dec 31, 2026paliperidone · Johnson & Johnson · phase 4 · NCT07493551
- Mar 31, 2027zeltiprone · Jazz Pharmaceuticals · phase 2 · NCT04541082
- Apr 5, 2027lumateperone · Johnson & Johnson · phase 3 · NCT05850689
- Sep 5, 2027Aripiprazole · Otsuka · phase 4 · NCT07547384
- Oct 2027lurasidone · Sumitomo Pharma · phase 4 · NCT07781293
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.